Eclipse Ingredients, led by dietitian-turned-entrepreneur Siobhan Coster, is a Brisbane-based biotechnology startup transforming the way high-value health ingredients are produced.
From MBA project to venture-backed company developing life-changing ingredients
Eclipse emerged from a unique collaboration with CSIRO, Australia's national science agency, where Siobhan's University of Queensland MBA project was incubated into a venture-backed biotechnology company.
Backed by the Queensland Government’s Female Founders Co-Investment Fund, the journey of Eclipse Ingredients is not just a testament to the power of innovation but also a shining example of the impact of women-led entrepreneurship in the biotechnology sector. Siobhan Coster’s story is one of determination, vision, and a deep commitment to improving global health and wellness through sustainable solutions.
A vision for the future
Eclipse Ingredients is reimagining ingredient production, starting with human lactoferrin, a powerful health protein that supports immunity, fights infection and boosts iron absorption. By leveraging precision fermentation, a sustainable production method using yeast instead of animals, the company is setting a new standard for scalability and quality in the biotechnology industry. This positions Eclipse to unlock ingredients that were previously inaccessible at scale, with applications spanning skincare, functional foods and infant nutrition.
Looking ahead, Eclipse has ambitious plans to expand its product portfolio and explore new applications for its groundbreaking technology. With the backing of lead investor AgFunder alongside substantial Australian Government support through Australia’s Food and Beverage Accelerator (FABA), the company is well-positioned to bring its first commercial products to market in 2027. Starting with high-performing skincare applications, Eclipse aims to revolutionise industries ranging from functional foods to infant nutrition and women’s health.
A catalyst for change
Siobhan’s journey from dietitian to entrepreneur is a powerful reminder of the potential for individuals to drive change when they combine passion with innovation. Her experience as a mother has further fuelled her commitment to creating health-beneficial ingredients that are accessible to all. By unlocking the potential of precision fermentation, Eclipse Ingredients is not only transforming the biotechnology landscape but also contributing to a healthier, more sustainable future for generations to come.
As Eclipse continues to grow, it serves as a beacon of what’s possible when science, entrepreneurship, and purpose align. With its sights set on global markets and a mission to make life-changing ingredients accessible to all, Eclipse Ingredients is poised to become a leader in the health and wellness industry, showcasing the power of Australian innovation on the world stage.
Inspiring the next generation
Siobhan’s success story is an inspiration for aspiring female entrepreneurs and innovators across Queensland and beyond. Her journey underscores the importance of collaboration, perseverance, and the willingness to challenge traditional methods in pursuit of a better future.
The Female Founders Co-Investment Fund has played a pivotal role in helping Eclipse Ingredients transition from a promising idea to a thriving biotechnology startup. By providing critical funding at an early stage, the grant has enabled Siobhan and her team to focus on refining their precision fermentation technology, securing intellectual property, and building a strong foundation for future growth. This targeted investment in women-led businesses highlights the importance of empowering female entrepreneurs to drive innovation and create meaningful change, and turn their ideas into reality.
About the Female Founders Co-Investment Fund
The Female Founders Co-Investment Fund is designed to empower women founders in Queensland by boosting the funds in early-stage capital raise projects.
Read more stories on Queensland’s innovators, scientists and entrepreneurs.
Last updated: 05 Feb 2026